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Background: Bacterial meningitis (BM) is characterized by an intense host inflammatory reaction, which contributes
to the development of brain damage and neuronal sequelae. Activation of the kynurenine (KYN) pathway (KP) has
been reported in various neurological diseases as a consequence of inflammation. Previously, the KP was shown to
be activated in animal models of BM, and the association of the SNP AADAT + 401C/T (kynurenine aminotransferase
II - KAT II) with the host immune response to BM has been described. The aim of this study was to investigate the
involvement of the KP during BM in humans by assessing the concentrations of KYN metabolites in the
cerebrospinal fluid (CSF) of BM patients and their relationship with the inflammatory response compared to aseptic
meningitis (AM) and non-meningitis (NM) groups.
Methods: The concentrations of tryptophan (TRP), KYN, kynurenic acid (KYNA) and anthranilic acid (AA) were
assessed by HPLC from CSF samples of patients hospitalized in the Giselda Trigueiro Hospital in Natal (Rio Grande
do Norte, Brazil). The KYN/TRP ratio was used as an index of indoleamine 2,3-dioxygenase (IDO) activity, and
cytokines were measured using a multiplex cytokine assay. The KYNA level was also analyzed in relation to
AADAT + 401C/T genotypes.
Results: In CSF from patients with BM, elevated levels of KYN, KYNA, AA, IDO activity and cytokines were observed.
The cytokines INF-γ and IL-1Ra showed a positive correlation with IDO activity, and TNF-α and IL-10 were positively
correlated with KYN and KYNA, respectively. Furthermore, the highest levels of KYNA were associated with the
AADAT + 401 C/T variant allele.
Conclusion: This study suggests a downward modulatory effect of the KP on CSF inflammation during BM.
Keywords: Bacterial meningitis, Kynurenine, IDO activity, CSF, Cytokines, AADAT + 401C/TIntroduction
Despite the advances in antimicrobial and intensive care
therapies against bacterial meningitis (BM), high mortal-
ity and morbidity rates have been observed [1]. Neuro-
logical sequelae, such as motor abnormalities, seizures,
learning and memory impairment and mental retard-
ation, are frequently reported after the disease. Cellular
damage, mainly in the cerebral cortex, hippocampus and
inner ear are the histomorphological correlates of these
neurofunctional deficits [2-4].* Correspondence: stephen.leib@ifik.unibe.ch; lfagnez@ufrnet.br
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unless otherwise stated.Bacterial invasion and proliferation within the cerebro-
spinal fluid (CSF) induce an intense inflammatory re-
sponse that leads to the activation of several metabolic
pathways. One such pathway is the kynurenine (KYN)
pathway (KP), which has been shown to be activated in
experimental pneumococcal meningitis [5,6]. The KP is
the major route for tryptophan (TRP) oxidative degrad-
ation, and this pathway is involved in several diseases of
the nervous system, including cancer, inflammatory dis-
orders and neurodegenerative diseases [7-10]. The first
step in the KP is the degradation of TRP catalyzed by
indoleamine 2,3-dioxygenase (IDO) to generate formylk-
ynurenine, which is rapidly converted into KYN by the ac-
tion of kynurenine formamidase. KYN can be partially
metabolized to kynurenic acid (KYNA) and anthranilic acidal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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respectively, and in part converted to 3-hydroxykynurenine
(3-HK) by kynurenine 3-monooxygenase. Kynureninase
also converts 3-HK to 3-hydroxyanthranilic acid (3-HAA),
the substrate for 3-hydroxyanthranilic acid oxidase, which
generates quinolinic acid (QUIN), the major substrate for
NAD+ de novo synthesis [8,9].
In the inflamed brain, TRP is metabolized through the
KP to form neuroactive metabolites such as QUIN, an
agonist of excitotoxic NMDA receptors, showing a cyto-
toxic effect, and KYNA, a neuroprotector antagonist of
these NMDA receptors [10,11]. Because the KP enzymes
are differentially expressed in several cell types, quantita-
tive differences in the production of neurotoxic and neu-
roprotective metabolites are observed [12-15], and an
unbalance in the KP has been associated with several
CNS diseases [7-10]. In an animal model of BM, the
chemical inhibition of the KP led to decreased cellular
NAD levels and increased apoptosis in the hippocampus
[6]. This was associated with high activity of PARP-1, a
DNA repair protein activated by DNA strand breaks
caused by oxidative stress during BM. PARP-1 uses
NAD+ as a cofactor, and its high activity induces ener-
getic depletion, leading to the cell death and neuronal
injury typical of BM [16]. Due to the involvement in
NAD+ de novo synthesis and KYNA production, the KP
is possibly a neuroprotective pathway in BM, despite its
neurotoxic metabolites [6].
Important immunomodulatory properties, mainly re-
lated to the immunosuppressive effect of IDO, have also
been attributed to this pathway [8,9,17]. A feedback mech-
anism in modulating the immune responses has been pro-
posed because proinflammatory stimuli activate the KP
and an anti-inflammatory effect mediated by KYNA has
been observed [8,18,19]. IDO is preferentially induced by
interferons, with IFN-γ being the main cytokine involved
in its induction. A synergistic effect of IL-1β, TNF-α and
IL-6 in IDO induction was also described. However, there
is evidence that IDO expression can also be induced by an
IFN-γ-independent mechanism that involves NF-κB and
stress-activated mitogen-activated protein (MAP) kinases,
such as p38 and c-Jun N-terminal kinase (JNK). Con-
versely, an immune-suppressive effect of the KP has also
been described. QUIN and 3-HAA induce the selective
apoptosis of TH1 cells through the activation of the cas-
pase pathway; B and NK cells are also susceptible to these
compounds. In addition, the expression of IDO in den-
dritic cells induces the generation of regulatory T-cells.
Thus, high levels of IDO will result in a decline of TH1 re-
sponse, accompanied by an enhanced TH2 response.
Moreover, KYNA shows an inhibitory effect on TNF-α at
the transcriptional level and as a ligand of GPR35. This in-
hibition of TNF-α by KYNA may be an important factor
in its neuroprotection [8,9].In a previous work, we identified the association of
the SNP AADAT + 401C/T (kynurenine aminotransfer-
ase II -– KAT II) with the host immune response to
BM, and our results suggested that this SNP may affect
the host’s ability to recruit leukocytes to the infection
site [20]. This evidence raises the hypothesis that the KP
plays an important role in the pathogenesis of BM in
humans. In the present work, we measured the concen-
trations of metabolites of the KP in CSF samples from
patients with meningitis and analyzed their correlation
with cytokines, inflammatory modulators previously re-
ported to regulate the pathogenesis of BM. We also in-
vestigated the correlation of KAT II genotypes with
KYNA levels and the disease.
Material and methods
Case selection and sample collection
This is a prospective study involving 28 patients with the
clinical suspicion of meningitis who were admitted to
the Giselda Trigueiro Hospital in Natal (Rio Grande do
Norte, Brazil), a reference center for infectious diseases.
Ethical approval for this study was given by Committees
on Medical Ethics of the Giselda Trigueiro Hospital and
by the National Committee in Ethics (CONEP) with num-
ber 0052.1.051.000-05. Informed consent was obtained
from each patient participating in this study. For child pa-
tients, informed consent was obtained from their parents
or legal guardians.
Lumbar puncture (LP) was performed to obtain CSF
for diagnostic purposes. Twenty-eight CSF samples were
collected at the time of admission. Immediately after
sampling, the CSF was kept at 4°C before centrifugation
(400 × g, 5 minutes, 4°C). The supernatant were immedi-
ately frozen and stored at −80°C until assayed. The CSF
samples were anonymized.
Thirteen patients were diagnosed with BM by the fol-
lowing criteria: (1) positive CSF bacterial culture, (2)
detection of the pathogen in the CSF by gram staining
plus clinical signs (acute onset, fever, meningeal irrita-
tion) and/or (3) positive blood culture or Gram stain in
the presence of clinical signs of meningitis, (4) positive
bacterial antigen detection in the CSF or blood using
the latex agglutination test, with clinical signs of men-
ingitis, and (5) clinical signs plus CSF parameters of in-
creased protein content (>40 mg/dL), reduced glucose
levels (<40 mg/dL) and the presence of CSF pleocytosis
(≥500 cells/mm3), with predominantly polymorpho-
nuclear granulocytes (PMN). Aseptic meningitis (AM)
was diagnosed in seven patients by acute onset, fever,
meningeal irritation signs, mild increase in protein con-
tent and normal glucose levels and the absence of the
detection of bacterial pathogens. Because LP is a very
invasive procedure, CSF samples were obtained only
from patients undergoing procedures for the diagnosis
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for CNS infection and were included as non-meningitis
controls (NM) (Table 1). Patients with confirmed acquired
immunodeficiency syndrome were excluded from this
study.Analysis of kynurenine by HPLC
CSF was analyzed by high-performance liquid chroma-
tography (HPLC) to quantify the levels of TRP, KYN,
KYNA and AA. Briefly, CSF samples were mixed 4:1
with 6% perchloric acid (PCA) to precipitate proteins.
The acidified samples were centrifuged 10,000 × g at 4°C
for 10 minutes, and the supernatant was filtered through
0.2-μm nylon membranes. An 80-μL aliquot of the filtrate
was applied onto a C18 reverse-phase HPLC column
(Supelcosil LC-18-DB, 15 cm× 4.6 mm, 3 μm; Supelco,
Buchs, Switzerland) with a guard column (Supelguard
LC-18-DB, 2 cm; Supelco, Buchs, Switzerland). TRP
metabolites were eluted isocratically at a flow rate of
0.8 mL/minute with a mobile phase consisting of 100 mM
zinc acetate and 3% acetonitrile (v/v), pH 6.2 [17,18]. TRP
and KYN were detected by UV absorption at 280 nm and
360 nm, respectively (L-4250 UV VIS Detector, Merck
Hitachi). AA and KYNA were detected by fluorescence
(F-1080 Fluorescence Detector, Merck Hitachi) at an ex-
citation of 344 nm and emission of 400 nm. Chromato-
grams were generated and analyzed using D-7000 HPLC
System Manager software.Cytokine multiplex measurements
The concentration of six cytokines (TNF-α, IL-6, IL-1β,
IFN-γ, IL-10 and IL-1Ra) was assessed in CSF samples
using the human cytokine Lincoplex Kit (HCYTO-60 K,
Lincoplex®, Linco Research Inc., St Charles, MA, USA)
with Luminex Technology (Bio-Plex 200 suspension array
system, Bio-Rad, Hercules, CA, USA). The assay was per-
formed according to the manufacturer’s instructions. Sam-
ples were diluted to fit within the dynamic range of the
assay. The cytokine concentrations were calculated by the
Bio-Plex Manager software using a five-parametric logistic
standard curve derived from the recombinant cytokine
standards provided in the kit.Table 1 Cerebrospinal fluid (CSF) parameters of patients with
Groups Non-meningitis, n = 8 B
Cell counte 2.4 ± 0.8 2
Proteine 23.5 ± 8.1 1
Glucosef 72.8 + 8.3d 2
Age (months)g 440.6 ± 85.8c 1
Mean ± SEM.
aP < 0.001 and bP < 0.05 significant values in the comparison to non-meningitis (NM
eP < 0.001 to one-way analysis with Kruskal-Wallis correction. fP < 0.001 and gP < 0.0Statistical analysis
Data were analyzed by analysis of variance (ANOVA),
with the Kruskal-Wallis test if needed (Prism 4.0, Graph-
Pad, San Diego, CA, USA). A P < 0.05 was considered to
be statistically significant. Multiple comparisons with
Tukey’s test were performed if the distribution was nor-
mal. Differences between two groups were analyzed with
the Mann–Whitney test when the distribution was not
normal and with Dunn’s post test when more than two
groups were analyzed. The table and graph data are pre-
sented as the median ± interquartiles when not following a
Gaussian distribution and the mean ± SEM when follow-
ing a Gaussian distribution.Results
Patients
Patients were divided into three groups, BM, AM and NM,
according to the diagnostic criteria (Table 1). The CSF pa-
rameters found in the BM group were significantly differ-
ent in comparison to those in the AM and NM groups.
BM was diagnosed in 13 patients, and the causative patho-
gens were Streptococcus pneumoniae (n = 7), Neisseria
meningitidis (n = 1) and Proteus mirabilis (n = 1); for 4 pa-
tients, the bacterial species could not be identified. Three
patients died during hospitalization. Two belonged to the
BM group and 1 to the AM group.Concentration of tryptophan and KYN metabolites
Compared to the levels found in NM, a significant in-
crease of KYN was observed in BM (P < 0.001) and AM
(P < 0.05) (Figure 1). The KYNA levels in CSF were found
to be significantly increased in BM compared to NM and
AM (P < 0.001 and P < 0.01, respectively) (Figure 1). The
CSF concentrations of AA showed significantly increased
levels in BM versus NM (Figure 1).
The ratio of KYN/TRP was calculated as an index of
IDO activity in the CSF samples. The ratio between KYN
and TRP determined in the CSF samples was significantly
increased in BM compared to NM (P < 0.001) (Figure 2).
AM showed no significant difference with regard to the
KYN/TRP ratio compared to NM. KYN concentrations
of NM patients that were below of the detection limit
(10 nM) were adjusted to this value.bacterial meningitis (BM) and aseptic meningitis (AM)
acterial meningitis, n = 13 Aseptic meningitis, n = 7
,468 ± 794.5ab 81.3 ± 38.0
71.2 ± 59.2ab 52.7 ± 20.8
9.4 ± 5.7 53.2 ± 5.5
59.4 ± 39.8 280.9 ± 72.5
) and AM respectively, and cP < 0.01 dP < 0.001 in the comparison of BM.
5 to one-way analysis of variance (ANOVA).
Figure 1 Tryptophan (TRP), kynurenine (KYN), kynurenic acid
(KYNA) and anthranilic acid (AA) concentrations in cerebrospinal
fluid (CSF) samples from human patients. Each metabolite was
analyzed independently between groups. Differences between
groups were analyzed with multiple comparison using Dunn’s post
test. P-value to one-way analysis with Kruskal-Wallis correction was
lower than P < 0.05 to all metabolites, except TRP. Values are
expressing as median ± interquartiles. ***P < 0.001 and *P < 0.05
compared to non-meningitis (NM); #P < 0.05 compared to aseptic
meningitis (AM). Values that were below the detection limit were
adjusted to the limit.
Figure 3 Comparison of the cytokines levels in the
cerebrospinal fluid (CSF) during meningitis. Values are expressing
as median ± interquartiles. Data showed P < 0.01 to one-way analysis
with Kruskal-Wallis correction. Differences between two groups were
analyzed with Dunn’s post test. ***P < 0.001, **P < 0.01 and *P < 0.05
compared to non-meningitis (NM). # P < 0.05 compared to aseptic
meningitis (AM).
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The concentrations of the six cytokines, IL-1β, IL-6,
TNF-α, IFN-γ, IL-10 and IL-1Ra, were significantly up-
regulated in CSF during BM when compared to the NM
control group (Figure 3). Despite the AM group show an
increase in some cytokines, for example, IL-6, TNF-α,
IL-10 and IL-1Ra, significant differences compared to
the NM group were not observed.
Furthermore, a positive correlation between the con-
centrations of IFN-γ and IL-1Ra with IDO activity was
found in the BM patients, as well as between TNF-α ver-
sus KYN and KYNA versus IL-10 (Table 2).Figure 2 Kynurenine to tryptophan (KYN/TRP) ratio indicates
indoleamine 2,3-dioxygenase (IDO) activity. Increased enzymatic
activity was found for IDO in cerebrospinal fluid (CSF) samples.
Values are expressing as median ± interquartiles. Data showed
P < 0.01 to one-way analysis with Kruskal-Wallis correction.
Differences between two groups were analyzed with Dunn’s
post test. Values that were below the detection limit were adjusted
to the limit.Correlation of genotype and KYNA levels
In a previous work, we obtained the genotype of these
patients in relation to SNP AADAT + 401C/T (KAT II)
and observed a high frequency of the T allele and TT
genotype in BM patients [20]. As the number of patients
in our study was small for polymorphism association, we
first analyzed all the patients in the study only according
to genotype. In this first analysis, the patients carrying
the T variant allele showed an increased KYNA concen-
tration (Figure 4A). Thereafter, the largest group of indi-
viduals, in this case the heterozygotes (CT), was divided
into two groups considering their disease, as shown in
Figure 4B. The obtained data showed the contribution of
acute BM combined with the variant allele in the in-
crease of KYNA levels. Individuals with acute BM were
also analyzed according to genotype, and the highest
KYNA levels were observed to be associated with the
TT genotype, however no significant difference was ob-
served (Figure 4C).
Discussion
CSF concentrations of KP metabolites have been demon-
strated in a variety of neurological diseases [7-10]. In the
present study, the concentration of TRP and three KYN
metabolites, IDO activity and cytokines were assessed in
the CSF of patients with meningitis. The obtained dataTable 2 Correlation of kynurenine to tryptophan (KYN/
TRP) ratio and KYN metabolites with cerebrospinal fluid
(CSF) cytokine levels in patients with bacterial meningitis
(BM)
IFN-γ TNF-α IL-10 IL-1RA
KYN/TRP ratio 0.77 - - 0.63
KYN - 0.77 - -
KYNA - - 0.57 -
P-value P < 0.01 P < 0.01 P < 0.05 P < 0.05
-Values mean the results obtained from Spearman’s correlation. Data did not
follow Gaussian distribution. Abbreviation: KYNA kynurenic acid.
Figure 4 Influence of the individual genotype on the levels of
kynurenic acid (KYNA). Patients showing polymorphisms in the
KAT II gene demonstrated increase in the KYNA concentration. All
patients in the study were split according genotype. (A) Patients
homozygous for variant allele (TT) showed higher KYNA
concentration than heterozygous (CT) and homozygous for wild
type allele (CC). (B) Patients with genotype CT were divided in two
groups according to disease showing the contribution of bacterial
meningitis (BM) combined with the variant allele in the elevated
concentration of KYNA. (C) Patients with BM were split according to
their genotype and KYNA levels were compared but no significant
difference was found. Values were expressed as mean ± SEM in
graph (A) and median ± interquartiles in (B) and (C). Data in graph
(A) showed Gaussian distribution and were analyzed with one-way
analysis of variance (ANOVA) with post test Tukey’s test to compare
all genotypes, while in graphs (B) and (C), differences between
groups were analyzed with the Mann–Whitney test and Dunn’s post
test, respectively.
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and suggested a role of IDO, kynureninase and anthra-
nilate 3-hydroxylase in accelerating the synthesis of KYN,
KYNA and AA in human BM patients, corroborating the
findings from animal models [5,6].
Inflammation in the CNS results in the recruitment of
activated T-cells and macrophages from the periphery
into the neural parenchyma [21]. Activated T-cells pro-
duce cytokine mediators of the inflammatory response, in-
cluding the macrophage-activating cytokine IFN-γ, which
induces IDO activity [22,23]. In our work, TRP levels are
not altered in the CSF of patients with BM or AM com-
pared to NM. However, efficient conversion of TRP to
KYN could be documented. IDO activity in the CSF was
significantly higher only in the BM group, in agreement
with the low IFN-γ level observed in the AM group. Con-
versely, a strong immune response during BM has been
positively correlated with IDO activity. In some non-
inflammatory and inflammatory diseases including BM,
the CSF QUIN, KYN and KYNA levels were also corre-
lated with immune markers, such as neopterin, white
blood cell counts and lgG levels, indicating a close rela-
tionship between the KP and the brain’s inflammatory re-
sponse [24].
Reports linking increased KYN metabolism with neur-
onal injury, particularly during neuroinflammatory dis-
ease, have emerged. This neuronal injury would be mainly
attributed to the production of neurotoxic metabolites
and oxidative molecules, such as superoxide anion and
hydrogen peroxide, during the metabolism of KYN
[7-10,25,26]. In contrast, in vitro studies have attributed
antioxidant activity to certain KP metabolites [27-29].
Due to these roles, the KP has been investigated as a tar-
get for therapeutic intervention. The pharmacological
modulation of KYN metabolism can affect de novo NAD
synthesis [6,30]. NAD is involved in many metabolic
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including PARP-1, which plays a crucial role in the devel-
opment of meningitis-associated central nervous system
complications [16]. In this sense, the KP intervention can
affect NAD production and consequently PARP-1 activity,
as the inhibition of the KP induced an increase in apop-
tosis in a BM animal model [6].
During the course of bacterial meningitis, anti-
inflammatory cytokines are produced to mitigate the
induced inflammation [4,31]. Some studies have proposed
that cells of the immune system use a bidirectional com-
munication in which TRP catabolism through IDO activity
drives the generation of IL-10-producing regulatory T-
cells [8,9,18,19]. In BM patients, we observed a positive
correlation between IDO activity and the inflammatory
cytokines IFN-γ and IL-1Ra (Table 2). Although each
cytokine displays different roles in the inflammation
during BM, IFN-γ seems to have a crucial role, mainly
during pneumococcal meningitis [32-35], showing to be
involved in deleterious proinflammatory effects [34,35].
Concomitantly, KYN metabolites showed a positive cor-
relation with TNF-α and KYNA metabolites with IL-10.
In contrast, AM did not show a strong immune re-
sponse or a high level of IL-10, despite a significant
amount of KYN in the comparison with the NM group.
Therefore, we propose that KYN metabolites alone are
not able to trigger the cascade of inflammatory mediator
production. In animal models, long-term diurnal hypoac-
tivity and nocturnal hyperactivity have been reported in
wild-type mice, while these changes were not observed in
IDO1(−/−) mice. However, no protection against develop-
ing long-term cognitive deficits was observed in IDO defi-
cient mice. These data suggest that KP may be involved in
some behavioural sequelae of pneumococcal meningitis
and may acts synergistically, or independently of, other
metabolic pathways to cause different types of neuro-
logical sequelae [36].
Recently, our group demonstrated that a polymorphism
in the kynurenine aminotransferase II gene (AADAT +
401C/T) was associated with reduced levels of TNF-α, IL-
1β, IL-6, MIP-1 /CCL3 and MIP-1/CCL4 in BM patients;
a reduction in cell count with a high correlation with cyto-
kine and chemokine levels was also observed, suggesting a
reduced leukocyte recruitment ability in these patients
[20]. This SNP is located in a putative exonic splicing si-
lencer (ESS), which may result in a quantitative increase
in the production of mRNAs and protein [37]. In agree-
ment with this proposition, analyzing the data from
KYNA measurements in the patients homozygous for the
TT genotype and comparing with the CC homozygous,
we observed an increase in KYNA levels (Figure 4).
Interestingly, our results demonstrated a positive correl-
ation between KYNA and IL-10, an anti-inflammatory
cytokine that was previously reported to down-regulatethe expression of proinflammatory cytokines such as
TNF-α. Similar data were obtained in a study carried
out by Hsieh et al., showing that KYNA improves the
outcomes of heatstroke in rats. In this model, KYNA
inhibited the expression of inflammatory molecules
such as TNF-α and ICAM-1 and enhanced IL-10 levels
[19]. Corroborating the findings regarding neuroprotection,
the reduced production of KYNA in astrocytes has been
proposed to increase neurological symptoms of cerebral
malaria [38]. KYNA was identified as a ligand for the re-
ceptor for GPR35, as it was able to attenuate LPS-induced
TNF-α secretion in a dose-dependent manner. Because the
TRP metabolic pathway is activated by proinflammatory
stimuli, the anti-inflammatory effect of KYNA suggests an
interesting feedback mechanism in modulating immune
responses [18].
In addition to cytokines, other molecules can regulate
the KP. There are known interactions between TRP deple-
tion and nitric oxide (NO) production. Several findings
have demonstrated that NO is able to inhibit the IDO en-
zyme by direct interaction or accelerating proteasomal
degradation [39,40]. Furthermore, as shown in the report
from Samelson-Jones and Yeh, several cellular factors,
including pH, redox environment, NO, and L-Trp abun-
dance can be considered as additional aspects in the
regulation of IDO activity [41].
Altogether, these findings suggest that IDO has promin-
ent importance during bacterial meningitis due to the fol-
lowing: its capacity to maintain PARP-1 activity through
NAD synthesis, protecting against cell death [6,16]; the
generation of reactive oxygen species (ROS), helping the
defense mechanisms in addition to maintaining IDO activ-
ity [8-10,26]; its capacity to produce some antioxidant me-
tabolites [27]; and regulating the immune response via the
known vessel-relaxing ability which KYN possess during
inflammation and other immunosuppressive mechanisms
[18,19,42]. We also suggest that AADAT + 401C/T pa-
tients can present a better outcome during BM disease via
a reduced inflammatory response and increased capacity
of the neuroprotective role of KYNA, which requires fur-
ther investigation. Conversely, this reduced response to a
pathogen at the beginning of infection may favor invasion
of the microorganism, increasing the susceptibility to BM.
However, the small number of patients analyzed and the
heterogeneity between the groups are limitations of our
work, making necessary further studies with a larger co-
hort for a better understanding of the role of KYNA in the
outcome of bacterial meningitis.
In conclusion, our results demonstrate a specific up-
regulation of the KP in BM patients and suggest that
KYN metabolites contribute directly to the disease. Des-
pite the neurotoxic properties reported in the literature
to date, we propose a positive and essential role of this
metabolic pathway in BM.
Coutinho et al. Journal of Neuroinflammation 2014, 11:169 Page 7 of 8
http://www.jneuroinflammation.com/content/11/1/169Competing interests
The authors declare that they have no competing interests.Authors’ contributions
LGC, SLL and LFAL proposed the study design. LGC, SC, CLB, FRSS, FLF and
DG performed the assays and data analysis. LGC, SC, SLL and LFAG wrote
the manuscript. All authors have read and approved the final version of the
manuscript.Acknowledgements
This work was supported by UBS Optimus Foundation and CNPq-Brazil. We
thank to Dr. Roney S Coimbra for participation in the initiation of the project.
We also thank the team of Hospital Giselda Trigueiro for their help with
sample collection. The authors LGC and LFAL are grateful to CNPq-Brazil for
the fellowships.
Received: 15 July 2014 Accepted: 17 September 2014
References
1. Auburtin M, Wolff M, Charpentier J, Varon E, Le Tulzo Y, Girault C,
Mohammedi I, Renard B, Mourvillier B, Bruneel F, Ricard JD, Timsit JF:
Detrimental role of delayed antibiotic administration and
penicillin-nonsusceptible strains in adult intensive care unit patients with
pneumococcal meningitis: the PNEUMOREA prospective multicenter
study. Crit Care Med 2006, 34:2758–2765.
2. Bedford H: Prevention, treatment and outcomes of bacterial meningitis
in childhood. Prof Nurse 2001, 17:100–102.
3. Lepage P, Dan B: Infantile and childhood bacterial meningitis. Handb
Clin Neurol 2013, 112:1115–1125.
4. Neal JW, Gasque P: How does the brain limit the severity of inflammation
and tissue injury during bacterial meningitis? J Neuropathol Exp Neurol
2013, 72:370–385.
5. Bellac CL, Coimbra RS, Christen S, Leib SL: Pneumococcal meningitis
causes accumulation of neurotoxic kynurenine metabolites in brain
regions prone to injury. Neurobiol Dis 2006, 24:395–402.
6. Bellac CL, Coimbra RS, Christen S, Leib SL: Inhibition of the kynurenine-NAD+
pathway leads to energy failure and exacerbates apoptosis in pneumococcal
meningitis. J Neuropathol Exp Neurol 2010, 69:1096–1104.
7. Fatokun AA, Hunt NH, Ball HJ: Indoleamine 2,3-dioxygenase 2 (IDO2) and
the kynurenine pathway: characteristics and potential roles in health
and disease. Amino Acids 2013, 45:1319–1329.
8. Mándi Y, Vécsei L: The kynurenine system and immunoregulation. J Neural
Transm 2012, 119:197–209.
9. Campbell BM, Charych E, Lee AW, Möller T: Kynurenines in CNS disease:
regulation by inflammatory cytokines. Front Neurosci 2014, 8:12.
10. Reyes Ocampo J, Lugo Huitrón R, González-Esquivel D, Ugalde-Muñiz P,
Jiménez-Anguiano A, Pineda B, Pedraza-Chaverri J, Ríos C, Pérez de la Cruz V:
Kynurenines with neuroactive and redox properties: relevance to aging
and brain diseases. Oxid Med Cell Longev 2014, 2014:646909.
11. Leib SL, Kim YS, Ferriero DM, Tauber MG: Neuroprotective effect of
excitatory amino acid antagonist kynurenic acid in experimental
bacterial meningitis. J Infect Dis 1996, 173:166–171.
12. Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ: Expression of the
kynurenine pathway enzymes in human microglia and macrophages.
Adv Exp Med Biol 2003, 527:105–512.
13. Guillemin GJ, Smythe G, Takikawa O, Brew BJ: Expression of indoleamine
2,3-dioxygenase and production of quinolinic acid by human microglia,
astrocytes, and neurons. Glia 2005, 49:15–23.
14. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ: Mechanism for quinolinic
acid cytotoxicity in human astrocytes and neurons. Neurotox Res 2009,
16:77–86.
15. Manéglier B, Malleret B, Guillemin GJ, Spreux-Varoquaux O, Devillier P,
Rogez-Kreuz C, Porcheray F, Thérond P, Dormont D, Clayette P: Modulation
of indoleamine-2,3-dioxygenase expression and activity by HIV-1 in
human macrophages. Fundam Clin Pharmacol 2009, 23:573–581.
16. Koedel U, Winkler F, Angele B, Fontana A, Pfister HW: Meningitis-associated
central nervous system complications are mediated by the activation of
poly(ADP-ribose) polymerase. J Cereb Blood Flow Metab 2002, 22:39–49.17. Puccetti P, Grohmann U: IDO and regulatory T cells: a role for reverse
signalling and non-canonical NF-kappaB activation. Nat Rev Immunol
2007, 7:817–823.
18. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L:
Kynurenic acid as a ligand for orphan G protein-coupled receptor
GPR35. J Biol Chem 2006, 281:22021–22028.
19. Hsieh YC, Chen RF, Yeh YS, Lin MT, Hsieh JH, Chen SH: Kynurenic acid
attenuates multiorgan dysfunction in rats after heatstroke. Acta
Pharmacol Sin 2011, 32:167–174.
20. de Souza FR, Fontes FL, da Silva TA, Coutinho LG, Leib SL, Agnez-Lima LF:
Association of kynurenine aminotransferase II gene C401T polymorphism
with immune response in patients with meningitis. BMC Med Genet 2011,
12:51.
21. Mucke L, Eddleston M: Astrocytes in infectious and immune-mediated
diseases of the central nervous system. Faseb J 1993, 7:1226–1232.
22. Schroten H, Spors B, Hucke C, Stins M, Kim KS, Adam R, Däubener W:
Potential role of human brain microvascular endothelial cells in the
pathogenesis of brain abscess: inhibition of Staphylococcus aureus by
activation of indoleamine 2,3-dioxygenase. Neuropediatrics 2001,
32:206–210.
23. Adam R, Rüssing D, Adams O, Ailyati A, Sik Kim K, Schroten H, Däubener W:
Role of human brain microvascular endothelial cells during central
nervous system infection. Significance of indoleamine 2,3-dioxygenase
in antimicrobial defence and immunoregulation. Thromb Haemost 2005,
94:341–346.
24. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA,
Elia J, Kruesi MJ, Lackner A, Larsen SA, Lee K, Leonard HL, Markey SP, Martin
A, Milstein S, Mouradian MM, Pranzatelli MR, Quearry BJ, Salazar A, Smith M,
Strauss SE, Sunderland T, Swedo SW, Tourtellotte WW: Quinolinic acid and
kynurenine pathway metabolism in inflammatory and non-inflammatory
neurological disease. Brain 1992, 115:1249–1273.
25. Hiraku Y, Inoue S, Oikawa S, Yamamoto K, Tada S, Nishino K, Kawanishi S:
Metal-mediated oxidative damage to cellular and isolated DNA by
certain tryptophan metabolites. Carcinogenesis 1995, 16:349–356.
26. Goldstein LE, Leopold MC, Huang X, Atwood CS, Saunders AJ, Hartshorn M,
Lim JT, Faget KY, Muffat JA, Scarpa RC, Chylack LT Jr, Bowden EF, Tanzi RE,
Bush AI: 3-hydroxykynurenine and 3-hydroxyanthranilic acid generate
hydrogen peroxide and promote alpha-crystallin cross-linking by metal
ion reduction. Biochemistry 2000, 39:7266–7275.
27. Christen S, Peterhans E, Stocker R: Antioxidant activities of some
tryptophan metabolites: possible implication for inflammatory diseases.
Proc Natl Acad Sci U S A 1990, 87:2506–2510.
28. Leipnitz G, Schumacher C, Dalcin KB, Scussiato K, Solano A, Funchal C,
Dutra-Filho CS, Wyse AT, Wannmacher CM, Latini A, Wajner M: In vitro
evidence for an antioxidant role of 3-hydroxykynurenine and 3-
hydroxyanthranilic acid in the brain. Neurochem Int 2007, 50:83–94.
29. Thomas SR, Stocker R: Antioxidant activities and redox regulation of
interferon-gamma-induced tryptophan metabolism in human monocytes
and macrophages. Adv Exp Med Biol 1999, 467:541–552.
30. Grant R, Kapoor V: Inhibition of indoleamine 2,3-dioxygenase activity in
IFN-gamma stimulated astroglioma cells decreases intracellular NAD
levels. Biochem Pharmacol 2003, 66:1033–1036.
31. Wennekamp J, Henneke P: Induction and termination of inflammatory
signaling in group B streptococcal sepsis. Immunol Rev 2008, 225:114–127.
32. Kornelisse RF, Hack CE, Savelkoul HF, van der Pouw Kraan TC, Hop WC, van
Mierlo G, Suur MH, Neijens HJ, de Groot R: Intrathecal production of
interleukin-12 and gamma interferon in patients with bacterial meningitis.
Infect Immun 1997, 65:877–881.
33. Glimaker M, Olcén P, Andersson B: Interferon-gamma in cerebrospinal
fluid from patients with viral and bacterial meningitis. Scand J Infec Dis
1994, 26:141–147.
34. Mitchell AJ, Yau B, McQuillan JA, Ball HJ, Too LK, Abtin A, Hertzog P, Leib SL,
Jones CA, Gerega SK, Weninger W, Hunt NH: Inflammasome-dependent
IFN-γ drives pathogenesis in Streptococcus pneumoniae meningitis.
J Immunol 2012, 189:4970–4980.
35. Too LK, Ball HJ, McGregor IS, Hunt NH: The pro-inflammatory cytokine
interferon-gamma is an important driver of neuropathology and
behavioural sequelae in experimental pneumococcal meningitis. Brain
Behav Immun 2014, 40:252–268.
36. Too LK, McQuillan JA, Ball HJ, Kanai M, Nakamura T, Funakoshi H, McGregor IS,
Hunt NH: The kynurenine pathway contributes to long-term
Coutinho et al. Journal of Neuroinflammation 2014, 11:169 Page 8 of 8
http://www.jneuroinflammation.com/content/11/1/169neuropsychological changes in experimental pneumococcal meningitis.
Behav Brain Res 2014, 270:179–195.
37. Kralovicova J, Vorechovsky I: Global control of aberrant splice-site activation
by auxiliary splicing sequences: evidence for a gradient in exon and intron
definition. Nucleic Acids Res 2007, 35:6399–6413.
38. Hunt NH, Golenser J, Chan-Ling T, Parekh S, Rae C, Potter S, Medana IM,
Miu J, Ball HJ: Immunopathogenesis of cerebral malaria. Int J Parasitol
2006, 36:569–582.
39. Hucke C, MacKenzie CR, Adjogble KD, Takikawa O, Daubener W: Nitric
oxide-mediated regulation of gamma interferon-induced bacteriostasis:
inhibition and degradation of human indoleamine 2,3-dioxygenase.
Infect Immun 2004, 72:2723–2730.
40. Entrena A, Camacho ME, Carrión MD, López-Cara LC, Velasco G, León J,
Escames G, Acuña-Castroviejo D, Tapias V, Gallo MA, Vivó A, Espinosa A:
Kynurenamines as neural nitric oxide synthase inhibitors. J Med Chem
2005, 48:8174–8181.
41. Samelson-Jones BJ, Yeh SR: Interactions between nitric oxide and
indoleamine 2,3-dioxygenase. Biochemistry 2006, 45:8527–8538.
42. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M,
Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, Kapoor V,
Celermajer DS, Mellor AL, Keaney JF Jr, Hunt NH, Stocker R: Kynurenine is
an endothelium-derived relaxing factor produced during inflammation.
Nat Med 2010, 16:279–285.
doi:10.1186/s12974-014-0169-4
Cite this article as: Coutinho et al.: The kynurenine pathway is involved
in bacterial meningitis. Journal of Neuroinflammation 2014 11:169.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
